Pembrolizumab/Lenvatinib Combo Shows Positive Clinical Activity in Recurrent Pleural Mesothelioma
August 7th 2022Pembrolizumab plus lenvatinib demonstrated promising clinical activity with no unexpected toxicities in patients with malignant pleural mesothelioma, according to results from the PEMMELA study.
Read More
Use of Neoadjuvant Chemoimmunotherapy Supported in Stage IIIA NSCLC
August 7th 2022Using neoadjuvant chemoimmunotherapy to treat patients with stage IIIA resectable non–small cell lung cancer based on differences between pathologic complete responders and non–pathologic complete responders is supported by the phase 2 NADIM trial.
Read More
Neoadjuvant Adagrasib With or Without Nivolumab May Better pCR Rates in NSCLC
August 6th 2022The phase 2 Neo-KAN study revealed neoadjuvant adagrasib alone or in combination with nivolumab may improve pathologic complete response rates in patients with resectable, KRAS G12C–mutated non–small cell lung cancer.
Read More
Where Will Tumor-Infiltrating Lymphocyte (TIL) Therapy Fit Into the Oncologic Landscape?
August 5th 2022In the first installment of the series, Allison Betof Warner, MD, PhD, reviews the mechanistic rationale behind tumor-infiltrating lymphocytes and considers where these experimental therapies may fit in the oncologic landscape.
Watch
Results of Amivantamab and Mobocertinib Trials Evaluated for Use in NSCLC
August 3rd 2022During a Targeted Oncology case-based roundtable event, Christine Bestvina, MD, discussed the outcomes of clinical trials of the EGFR exon 20-targeted agents amivantamab and mobocertinib with participants. This is the second of 2 articles based on this event.
Read More
Subcutaneous Atezolizumab Non-Inferior to IV Formulation in Locally Advanced or Metastatic NSCLC
August 2nd 2022In the phase 3 IMscin001 clinical trial, the use of subcutaneous atezolizumab demonstrated similar efficacy, safety, and pharmacokinetics compared with intravenous atezolizumab in patients with immunotherapy-naïve locally advanced or metastatic non—small cell lung cancer.
Read More
Exploring Subset Analyses in the EMPOWER-Lung 1 Trial for NSCLC
July 29th 2022During a live virtual event, Martin F. Dietrich, MD, PhD, discussed the results of the EMPOWER-Lung 1 and EMPOWER-Lung 3 trials of cemiplimab for non–small cell lung cancer. This is the second of 2 articles based on this event.
Read More
Clinical Commentary: How Immunotherapy Is Used for Treatment of Patients with ES-SCLC and NSCLC
July 27th 2022At a live virtual event, Devika Das, MD, discussed the use of immunotherapy for patients with extensive stage-small cell lung cancer (ES-SCLC) and for patients with non–small cell lung cancer.
Read More
Advanced Squamous NSCLC Survival Improved With Chemoimmunotherapy Regardless of PD-L1 Expression
July 20th 2022During a live virtual event, Adam M. Schoenfeld, MD, discussed results of the KEYNOTE-407 trial of patients with advanced squamous non–small cell lung cancer in terms of PD-L1 expression. This is the second of 2 articles based on this event.
Read More
Immunotherapies Offer Alternatives to Chemotherapy for PD-L1–High Lung Cancer
June 27th 2022During a Targeted Oncology live virtual event, Martin F. Dietrich, MD, PhD, discussed data from 3 trials of immunotherapy agents for patients with non–small cell lung cancer with high PD-L1 expression.
Read More
Overcoming Resistance to ICI Therapy With Ramucirumab and Pembrolizumab in Advanced NSCLC
June 27th 2022In an interview with Targeted Oncology™, Karen L. Reckamp, MD, discussed that limited options for patients with advanced NSCLC who are resistant to immune checkpoint inhibitor therapy. Reckamp also discusses how Lung-MAP research might play a hand in bringing new therapies in the future.
Read More
Tazemetostat Results Signal the Utility of Biomarker-Driven Therapy for BAP1-Inactivated MPM
June 24th 2022Results from a study of tazemetostat in patients with BAP1-inactivated malignant pleural mesothelioma show the feasibility of molecularly-stratified therapy for patients with relapsed or refractory disease.
Read More
Chemoimmunotherapy Shows 3-Year Survival Benefit for Advanced NSCLC
June 22nd 2022During a live virtual event, Adam J. Schoenfeld, MD, discussed the updated 3-year results of the CheckMate 9LA trial of nivolumab, ipilimumab, and 2 cycles of chemotherapy for patients with advanced non–small cell lung cancer.
Read More
Part 2: Considerations for Using Adjuvant Chemotherapy and Osimertinib in NSCLC
June 13th 2022During a live virtual event, Aaron E. Lisberg, MD, discussed the use of adjuvant chemotherapy regimens and the significance of the ADAURA trial of osimertinib for patients with early-stage non–small cell lung cancer with certain EGFR mutations.
Read More